EpiBone
Nina Tandon, PhD/MBA, is the CEO and co-founder of EpiBone, Inc., a leading biotech company specializing in regenerative medicine. Nina has been with the company since 2014, where they lead the development of bone reconstruction solutions using tissue engineering. Prior to joining EpiBone, Dr. Tandon worked as an Associate Adjunct Professor of Electrical Engineering at The Cooper Union for the Advancement of Science and Art from 2007 to 2014, teaching courses on Bioelectricity. Nina also served as an Associate at McKinsey & Company from 2008 to 2010.
Nina Tandon, PhD/MBA, has a strong educational background in the fields of biomedical engineering, tissue engineering, business administration, and electrical engineering. Nina began their academic journey at The Cooper Union for the Advancement of Science and Art, where they earned a Bachelor of Science degree in Electrical Engineering in 2001. In 2003, they were awarded a Fulbright Fellowship and studied Electrical and Electronics Engineering at the University of Rome Tor Vergata.
Continuing their education, Tandon pursued a Master of Science degree in Bioelectrical Engineering at the Massachusetts Institute of Technology from 2004 to 2006. Nina then moved on to Columbia Engineering, where they obtained their PhD in Biomedical Engineering from 2006 to 2009.
Realizing the importance of business knowledge, Tandon furthered their education at Columbia Business School, where they pursued a Master of Business Administration degree from 2011 to 2012. Finally, they engaged in post-doctoral research in Tissue Engineering at Columbia Engineering from 2010 to 2014.
Through their diverse educational experiences, Tandon has developed a well-rounded perspective that integrates scientific, engineering, and business principles, allowing their to excel in interdisciplinary fields that blend technology and entrepreneurship.
This person is not in any teams
EpiBone
3 followers
EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.